Despite the change in fortunes, Ascension signaled that it is not yet out of the woods, noting that “consumer confidence and healthcare hesitation as a result of COVID-19 continue to affect Ascension markets, to varying degrees.”
Gov. Eric Holcomb’s coronavirus stance drawing criticism
The Republican has said repeatedly that he’d be willing to take a step back in the phased-in reopening if key data indicated the pandemic was worsening. But he has never made good on that threat.Read More
Experts aim to predict trajectory of COVID deaths in coming months
In the absence of a crystal ball, forecasting models offer the next best thing: a rough guide for people to guess when they might get back to something resembling normalcy.Read More
Under the Affordable Care Act, health insurers are required to spend 80% to 85% of the revenue they get from premiums on medical care. If they don’t, they have to issue rebates or credits to make up the difference.
Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still-ongoing study.
The federal government says readmissions are often unnecessary and cost taxpayers tens of billions of dollars a year for treatments that should have been caught the first time around, or were not followed up adequately.
Indiana lags much of the nation in flu vaccination rates, and some public health officials say the combination of flu and coronavirus illness could overwhelm hospitals this winter.
Chicago Mayor Lori Lightfoot says she isn’t sure the governor’s new restrictions are targeting the right people and worries that they will adversely affect the city’s economy.
The state on Monday reported 13 more deaths due to COVID-19. The seven-day moving average for cases has reached an all-time high of 2,215.
State statistics reveal a very uneven, lumpy picture for COVID-19 cases from county to county, and the picture is constantly shifting.
A panel of experts spoke at IBJ’s Life Sciences Power Breakfast, which took place virtually Oct. 9, talked about venture capital in the life sciences sector. These are some excerpts.
The new company, contract drug developer INCog Biopharma, plans to build a $60 million facility and hire up to 150 workers by the end of 2024.
It’s that time of year, when workers gather in the conference room (or through a zoom video conference) and brace for the latest news on health insurance plans.
The hospital system has filed a petition for vacation of several streets, meaning it wants to close or privatize them and fold them into the new campus.
Indianapolis-based US Water Systems has pivoted to devise a high-tech method to purify the air through which the virus is often spread.
Like many other providers, Ascension suspended all elective, nonessential medical and surgical procedures for several months to prepare for the surge of COVID-19 patients, reducing volume and revenue.
The joint-venture announcement by partners Community Health Network and Kindred Healthcare comes less than a month after the partners closed another rehabilitation hospital, Community Howard Specialty Hospital and Replay Physical Therapy in Kokomo.
Hospital systems say their aim is to provide a helpful clearinghouse for patients in need of housing, transportation, food and other critical services—factors sometimes called “social determinants of health.”
Indianapolis-based Hc1.com, which makes software that helps health care organizations interpret data to personalize care and control costs, said it thinks it has a solution that will help major U.S. colleges and universities control coronavirus outbreaks on campus.
Just 12 years after opening to great fanfare, the future of the $150 million center, a partnership between the Indiana University School of Medicine and Indiana University Health, is full of questions.
Entrepreneur Katara McCarty says the Exhale app she developed “speaks to the path of women of color.”
Lilly and partner Boehringer Ingelheim published results from a trial showing the drug cut the risk of cardiovascular hospitalizations or death by 25%, compared to placebo in heart failure patients.